MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Hallucinations"

  • 2017 International Congress

    Treatment of Psychosis in Parkinson’s Disease: Evidence-Based Recommendations Versus Actual Clinical Practice

    L.G. Chan, A. Kong, L. Tan (Singapore, Singapore)

    Objective: To examine if actual clinical practice of antipsychotic use in Parkinson's Disease patients are consistent with published evidence-based reviews of treatment recommendations and discuss…
  • 2017 International Congress

    Minor hallucinations in Parkinson’s disease: neuropshycological and neurophysiological correlates in a representative sample of non-demented patients.

    J. Pagonabarraga, J. Marin-Lahoz, A. Horta, H. Bejr-Kasem, M. Cornella, J. Pérez-Pérez, S. Martinez-Horta, J. Kulisevsky (Barcelona, Spain)

    Objective: To study the neuropsychological and neurophysiological correlates of minor hallucinations (mH) in non-demented PD patients, by using different scales and the event-related potentials (ERP)…
  • 2017 International Congress

    What do patients with Parkinson’s disease see in their hallucinations? Classification of hallucinations which are seen in Parkinson’s Disease; Single Center Experience

    A. Acarer, S. Ciftci, Z. Colakoglu (Izmir, Turkey)

    Objective: Our purpose is to evaluate  and classify visiual hallucination of  52 patients with Parkinson' s Disease  and to detect if there is any relation between…
  • 2017 International Congress

    A Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Dementia with Lewy Bodies and Parkinson’s Disease Dementia Subjects Experiencing Visual Hallucinations

    S. Ramaswamy, W. Wen, G. Ramaswamy, L. Friedhoff (New York, NY, USA)

    Objective: To evaluate the safety and efficacy of nelotanserin in Lewy body dementia subjects experiencing visual hallucinations. Background: Nelotanserin is a selective 5HT2A receptor inverse…
  • 2017 International Congress

    Aberrant resting state functional brain networks in patients with Parkinson’s disease and visual hallucinations

    A. Lenka, R. Panda, L. George, S. Hegde, S. Arumugham, J. Saini, R. Bharath, P. Pal (Bangalore, India)

    Objective:  To explore the neural correlates of Visual Hallucinations (VH) in patients with Parkinson’s disease (PD). Background: Psychosis is one of the commonly observed non-motor…
  • 2017 International Congress

    Decreased Fronto-Parietal connection is associated with face pareidolia in Parkinson’s disease.

    Y. Kajiyama, M. Mihara, Y. Mitani, H. Otomune, H. Fujimoto, G. Revankar, K. Konaka, H. Mochizuki (Osaka, Japan)

    Objective: To investigate the neural mechanism of face pareidolia in Parkinson’s disease (PD) patients using resting state functional magnetic resonance imaging (rs-fMRI). Background: Face pareidolia…
  • 2017 International Congress

    Neural correlates of minor hallucinations in Parkinson’s disease: A multimodal imaging study

    H. Bejr-kasem, J. Pagonabarraga, S. Martinez-Horta, F. Sampedro, J. Marin-Lahoz, J. Perez-Perez, A. Horta-Barba, B. Pascual-Sedano, J. Kulisevsky (Barcelona, Spain)

    Objective: To explore the neural correlates sub-serving isolated minor hallucinations in Parkinson's disease (PD) through a multimodal structural and functional neuroimaging approach based on grey matter…
  • 2017 International Congress

    Parkinson’s disease with visual hallucination: optic radiation abnormalities on phase difference-enhanced imaging (PADRE)

    M. Miyata, S. Kakeda, T. Yoneda, H. Narimatsu, T. Sato, K. Okada, H. Adachi, Y. Korogi (Kitakyushu, Japan)

    Objective: We assessed structural abnormalities of optic radiation (OR) in patients with Parkinson disease (PD) with dementia (PDD) and dementia with lewy bodies (DLB) by…
  • 2017 International Congress

    Does gender influence the expression of non-motor symptoms in Parkinson’s disease?: An observational study

    J. Herreros Rodríguez, A. Esquivel López, R. Gordo Mañas, Á. Sánchez Ferro (Madrid, Spain)

    Objective: Our goal was to evaluate how gender influenced the expression of non-motor symptoms in a sample of PD patients. Background: Parkinson’s Disease (PD) is defined…
  • 2017 International Congress

    The highly-selective metabotropic glutamate receptor 2 positive allosteric modulator LY-487,379 alleviates psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset

    L. Sid-Otmane, S. Nuara, A. Hamadjida, N. Veyres, C. Rouillard, M. Panisset, J. Gourdon, P. Huot (Montreal, QC, Canada)

    Objective: To investigate the effect of metabotropic glutamate receptor 2 (mGluR2) activation on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced psychosis-like behaviours (PLBs) and dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley